Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-87801493 in Combination With CD3 T-Cell Engagers in Relapsed/Refractory B-cell Non-Hodgkin Lymphoid Malignancies
NCT06139406Phase 1Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2023
- Primary completion
- Jan 2026
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 1, open-label trial of JNJ-87801493 in non-Hodgkin lymphoma (NHL) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Dose Limiting Toxicity and Adverse Events. Started Dec 2023; status: active, not recruiting.
02
Drugs
JNJ-87801493
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT06139406.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06139406.